Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative intraperitoneal raltitrexed for prevention of postoperative peritoneal metastasis in colorectal cancer
ChiCTR1800019739Phase 4Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of raltitrexed in colorectal cancer (CRC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 3-year peritoneal metastasis rate. Started Dec 2018; status: recruiting.
02
Drugs
raltitrexed
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1800019739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019739.